2Yrd. Doç. Dr., Fırat Üniversitesi, Göz Hastalıkları, Elazığ, Türkiye
3Uz. Dr., Ankara Eğitim ve Araştırma Hastanesi, Göz Hastalıkları, Ankara, Türkiye
4Prof. Dr., Fırat Üniversitesi, Göz Hastalıkları, Elazığ, Türkiye
5Doç. Dr., Fırat Üniversitesi, Göz Hastalıkları, Elazığ, Türkiye Purpose: To evaluate the effect of ranibizumab on exudative AMD after the fi rst and the second years and compare them with baseline and each other.
Methods: 63 eyes of 49 patients who were treated between January 2011 and March 2013 were evaluated. 0.05 ml ranibizumab (Lucentis; Novartis,Basel,Switzerland and Genentech Inc.,Sounth San Francisco,CA) was administered during the first and the second years. CFT and BCVA were compared with baseline after 12 and 24 months respectively. Comparison with baseline and each other were performed.
Results: The mean age of the 49 patients was 74.3±7,1. The mean BCVA and CFT of 63 eyes were 0.7±0.9 LogMAR and 416±274 μm respectively, during baseline. They were 0.8 LogMAR and 311 μm ±139 μm after 12 months. However the mean BCVA didn’t change after 12 months vs the baseline (p:0.5). The mean CFT significantly decreased after 12 months (p=0.003). 25 patients continued to attend. 31 eyes of these 25 patients were treated in the second year. The mean BCVA and the mean CFT of these eyes were 0.8 ± 0.6 LogMAR and 415,2±219.7 μm respectively,during baseline. They were 0.7 ± 1.0 LogMAR and 266±101 μm respectively after 24 months(p:0.94). Although the mean BCVA of the 31 eyes didn’t change vs the baseline, the mean CFT signifi cantly decreased at the end of the second year( p=0.0006). When the first and the second year results were compared, we observed that the mean BCVA didn’t change, but the mean CFT continued to decrease(p:0,01).
Conclusion: We observed significant anatomical healing after two years.
Keywords : Ranibizumab, wet AMD